ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

IsoRay, Inc.

350 Hills Street
Suite 106
Richland, WA 99354
United States

IndustryMedical Instruments & Supplies
Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Mr. William Cavanagh IIICOO & Chief Scientific Officer209.77kN/A1966
Mr. Michael L. KrachonVP of Sales & Marketing234kN/A1971
Ms. Lori A. Holmes-WoodsInterim Chief Exec. OfficerN/AN/A1962
Mr. Mark Austin CPAPrincipal Accounting & Financial Officer and ControllerN/AN/A1987
Mrs. Jennifer StreeterVP of HRN/AN/A1970
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.

Corporate Governance

IsoRay, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.